Hyphens Pharma International Ltd – Assembling Multiple Growth Engines - Trader Hub | I3investor

Sign In

Trader Hub

Blog Headlines (by Date) Blog Index

Hyphens Pharma International Ltd – Assembling Multiple Growth Engines

  • FY22 results exceeded expectations. FY22 revenue and PATMI were 109%/118% of our forecasts. Revenue jumped across all segments in 2H22, in part driven by pent-up demand after the re-opening. Dividends surged by 66% to 1.11 cents.
  • We believe the re-opening saw the return of surgeries deferred during the pandemic, and increased visits drove specialty pharma revenue. Around 86% of FY22 earnings is from specialty pharma.
  • We raise FY23e earnings by 31% to S$13.2mn and the DCF target price is nudged up to S$0.445 (prev. S$0.43). Our BUY recommendation is maintained. We underestimated the rebound in sales post re-opening. Hyphens has assembled multi-franchise drivers in the medium term, namely DocMed, proprietary skincare brands and specialty pharma distribution into public sector verticals. A near-term headwind is the upfront costs to develop the DocMed healthcare platform.



The Positive

+ Strong growth in specialty pharma. The largest earning driver was specialty pharma. EBITDA more than doubled to S$7.9mn with the inclusion of recently acquired Novem. We believe the re-opening has increased surgeries and visits to hospitals and specialists, thereby driving up revenue.

The Negative

– Softer proprietary margins. EBITDA margins for proprietary brands declined by 1.4% points YoY to 7.4% in 2H22. We believe higher production and product development costs contributed to the weakness in margins.



We expect slower growth post the pent-up demand after the re-opening. New products launched will support sales, such as Nabota® (botox), Meradan® (steroid eczema cream) and Winlevi® (acne cream). Hyphens continue to build medium-term franchises: (i) DocMed – a platform for doctors, drug companies and other healthcare providers; (ii) Proprietary brands in skin health products; (iii) Novem – expand specialty products distribution into the public sector.

Source: Phillip Capital Research - 9 Mar 2023

Share this

Related Stocks

Chart Stock Name Last Change Volume
Hyphens Pharma 0.28 0.00 (0.00%) 2,000
  Be the first to like this.

286  207  220  678 

Top 10 Active Counters
 Seatrium 0.134+0.003 
 HSI 19000MBeC.. 0.071+0.02 
 HSI 16600MBeP.. 0.061-0.022 
 NikkoAM-STC A.. 0.809+0.009 
 HSI 15600MBeP.. 0.079-0.018 
 CapAllianz 0.0020.00 
 Rex Intl 0.1960.00 
 YZJ Shipbldg SGD 1.66-0.01 
 RH PetroGas 0.23+0.025 
 Genting Sing 0.845-0.01 


1. Singapore Considering Novel Carbon Credits for Coal Phaseout in Asia CEO Morning Brief
2. 3 Things You Need to Keep in Mind when Building Your REIT Investment Portfolio THE SINGAPOREAN INVESTOR
3. Potential Special Dividends from Singtel (SGX: Z74) reitsnewsletter
4. Blueprint for Prosperity: How to Set Financial Goals and Guage Success Effectively Collin Seow Remisier Blog
5. Singapore Aug Core Inflation Rises 3.4%, Seen Easing CEO Morning Brief